SNYR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the provided data, Synergy CHC Corp (SNYR) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company is facing significant financial challenges, with declining revenue, net income, and EPS. Technical indicators show a bearish trend, and there are no strong positive catalysts or trading signals to suggest a reversal in the near term. Additionally, there is no recent news or congressional trading activity to support a bullish outlook.
The technical indicators for SNYR are bearish. The MACD is below 0 and negatively contracting, RSI is at an oversold level of 11.97, and moving averages indicate a downtrend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 0.407, with resistance levels at 0.576 and 0.744.
The only positive catalyst is the analyst's Buy rating and a $5 price target, citing large market opportunities for the company's brain health supplement FOCUSfactor.
The company has reported a significant decline in financial performance in Q4 2025, with revenue down 40.95% YoY, net income down 14121.44% YoY, and EPS down 13200.00% YoY. Gross margin also dropped by 42.78%. Technical indicators are bearish, and there is no recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q4 2025, the company's revenue dropped to $6,065,167 (-40.95% YoY), net income dropped to -$14,816,035 (-14121.44% YoY), EPS dropped to -1.31 (-13200.00% YoY), and gross margin dropped to 36.04% (-42.78% YoY). These figures indicate severe financial struggles.
Ascendiant analyst Edward Woo initiated coverage with a Buy rating and a $5 price target, citing market opportunities for the company's brain health supplement FOCUSfactor. However, this is the only analyst rating available, and it does not outweigh the company's poor financial performance and bearish technical indicators.
